| [1] |
Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: de novo neoplasms after liver transplantation[J]. Curr Opin Organ Transplant, 2018, 23(2):187-195．
|
| [2] |
González JP, Zabaleta A, Sangro P, et al. Immunophenotypic pattern of de novo malignancy after liver transplantation[J]. Transplant Proc, 2019, 51(1):77-79.
|
| [3] |
Allaire M, Sérée O, Coilly A, et al. De novo primary liver cancer after liver transplantation: a French national study on 15 803 patients[J]. Exp Clin Transplant, 2018, 16(6):779-780.
|
| [4] |
Taborelli M, Piselli P, Ettorre GM, et al. Survival after the diagnosis of de novo malignancy in liver transplant recipients[J]. Int J Cancer, 2019, 144(2):232-239.
|
| [5] |
陈学燕，李利亚．多原发恶性肿瘤临床特点及发病机制的研究进展[J]．中日友好医院学报，2019, 33(1):41-44.
|
| [6] |
Skelton WP 4th, Ali A, Skelton MN, et al. Analysis of overall survival in patients with multiple primary malignancies: a single-center experience[J]. Cureus, 2019, 11(4):e4552.
|
| [7] |
Shuayb M, Reza MS. Prolonged survival with maintenance pemetrexed for a multiple primary malignancy[J]. BMJ Support Palliat Care, 2019, 9(1):51-53.
|
| [8] |
Kricker A, Armstrong BK, Goumas C, et al. Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study[J]. JAMA Dermatol, 2013, 149(8):921-927.
|
| [9] |
饶伟，解曼，刘东岳，等．中国肝移植术后新发恶性肿瘤文献分析报告[J/CD]．中华移植杂志（电子版），2018, 12(4):165-169.
|
| [10] |
张志军，钟海钢，张微，等．肝移植术后新发消化系统恶性肿瘤的诊治十例[J]．中华器官移植杂志，2016, 37(9):513-517.
|
| [11] |
王旭，陈虹，王乐天，等．原位肝移植术后新发肿瘤三例报告并文献复习[J]．中国急救复苏与灾害医学杂志，2009, 4(7):484-486.
|
| [12] |
易述红，易慧敏，傅斌生，等．肝移植术后新发恶性肿瘤的发生和防治（附九例报告）[J/CD]．中华肝脏外科手术学电子杂志，2014, 3(3):148-151．
|
| [13] |
Sérée O, Altieri M, Guillaume E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients[J]. Liver Transpl, 2018, 24(10):1425-1436.
|
| [14] |
Imai D, Yoshizumi T, Sakata K, et al. Long-term outcomes and risk factors after adult living donor liver transplantation[J]. Transplantation, 2018, 102(9):e382-391.
|
| [15] |
Rousseau B, Guillemin A, Duvoux C, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma[J]. Int J Cancer, 2019, 144(4):886-896.
|
| [16] |
Rademacher S, Seehofer D, Eurich D, et al. The 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients[J]. Liver Transpl, 2017, 23(11):1404-1414．
|